Source:http://linkedlifedata.com/resource/pubmed/id/15197779
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2004-6-15
|
pubmed:abstractText |
While several studies have reported that thymidylate synthase (TS) tumour expression can be a reliable predictive marker of clinical response to 5-Fluorouracil (5-FU) for advanced colorectal cancer patients, only a few studies that searched for predictive factors of irinotecan (CPT-11) clinical response are available. The aim of the present study has been to verify the predictive value of immunohistochemical topoisomerase-I (Topo-I) and TS primary tumour expression in a consecutive series of 62 advanced colorectal cancer patients that received a first line 5-FU/CPT-11 chemotherapy. TS and Topo-I immunostaining was observed in 76% and 43% of tumours, respectively, resulting in a significant relationship within each tumour (r=0.365, p<0.004). Patients with different TS tumour expression showed a similar percentage of Objective Clinical Response, OR (40% vs. 28% of OR in low and high TS-expressing tumours, respectively, p=ns); also, patients with different Topo-I tumour expression did not show a different probability of OR (39% vs. 29% of OR in high and low Topo-I expressing tumours, respectively; p=ns). The tumour expression of these 2 biomarkers also did not impact on time to progression and overall survival of patients. Furthermore, the combined analysis of TS and Topo-I tumour status did not permit to individualize subgroups of patients with different probability of OR. With multivariate analysis, only patient Performance Status significantly impacted on OS (Hazard ratio 4.87; p=0.02) of these patients. We can conclude that high TS tumour expression seems not to preclude a clinical activity for 5-FU/CPT-11 polichemotherapy in advanced colorectal cancer patients; furthermore, clinical response and prognosis of colorectal cancer patients treated with 5-FU/CPT-11 regimen do not differ in tumours with different TS or Topo-I expression.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Topoisomerases, Type I,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Thymidylate Synthase,
http://linkedlifedata.com/resource/pubmed/chemical/irinotecan
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0020-7136
|
pubmed:author |
pubmed-author:ChiriattiAnnalisaA,
pubmed-author:ColucciGiuseppeG,
pubmed-author:GiulianiFrancescoF,
pubmed-author:MaielloEvaristoE,
pubmed-author:MangiaAnitaA,
pubmed-author:MontemurroSeverinoS,
pubmed-author:ParadisoAngeloA,
pubmed-author:SimoneGianniG,
pubmed-author:XuJanMingJ,
pubmed-author:ZitoAlfredoA
|
pubmed:copyrightInfo |
Copyright 2004 Wiley-Liss, Inc.
|
pubmed:issnType |
Print
|
pubmed:day |
20
|
pubmed:volume |
111
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
252-8
|
pubmed:dateRevised |
2009-11-3
|
pubmed:meshHeading |
pubmed-meshheading:15197779-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15197779-Camptothecin,
pubmed-meshheading:15197779-Colorectal Neoplasms,
pubmed-meshheading:15197779-DNA Topoisomerases, Type I,
pubmed-meshheading:15197779-Female,
pubmed-meshheading:15197779-Fluorouracil,
pubmed-meshheading:15197779-Gene Expression Profiling,
pubmed-meshheading:15197779-Humans,
pubmed-meshheading:15197779-Infusions, Intravenous,
pubmed-meshheading:15197779-Injections, Intravenous,
pubmed-meshheading:15197779-Leucovorin,
pubmed-meshheading:15197779-Male,
pubmed-meshheading:15197779-Multivariate Analysis,
pubmed-meshheading:15197779-Prognosis,
pubmed-meshheading:15197779-Thymidylate Synthase,
pubmed-meshheading:15197779-Treatment Outcome
|
pubmed:year |
2004
|
pubmed:articleTitle |
Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.
|
pubmed:affiliation |
Clinical Experimental Oncology Laboratory, National Cancer Institute-Bari, Bari, Italy. paradiso.io.bari@virgilio.it
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|